In vitro and in vivo studies have demonstrated that the bacteriologic efficacy of once-daily aminoglycoside therapy is equivalent to that achieved with conventional multiple daily dosing. The impact of once-daily dosing for meningitis has not been studied. Using the well-characterized rabbit meningitis model, we compared two regimens of the same daily dosage of gentamicin given either once or in three divided doses for 24 or 72 h. The initial 1 h mean cerebrospinal fluid (CSF) gentamicin concentration for animals receiving a single dose (2.9 ؎ 1.7 g/ml) was threefold higher than that for animals receiving multiple doses. The rate of bacterial killing in the first 8 h of treatment was significantly greater for the animals with higher concentrations in their CSF (؊0.21 ؎ 0.19 versus ؊0.03 ؎ 0.22 log 10 CFU/ml/h), suggesting concentration-dependent killing. By 24 h, the mean reduction in bacterial titers was similar for the two regimens. In animals treated for 72 h, no differences in bactericidal activity were noted at 24, 48, or 72 h. Gentamicin at two different dosages was administered intracisternally to a separate set of animals to achieve considerably higher CSF gentamicin concentrations. In these animals, the rate of bacterial clearance in the first 8 h (؊0.52 ؎ 0.15 and ؊0.58 ؎ 0.14 log 10 CFU/ml/h for the lower and higher dosages, respectively) was significantly greater than that in animals treated intravenously. In conclusion, there is evidence of concentration-dependent killing with gentamicin early in treatment for experimental E. coli meningitis, and once-daily dosing therapy appears to be at least as effective as multiple-dose therapy in reducing bacterial counts in CSF.
In the past 15 years, much attention has been focused on once-daily (OD) administration of aminoglycosides. At the time that these antibacterial agents were introduced into clinical use, dosing regimens were designed to maintain serum antibiotic concentrations above the MIC for the majority of the dosing interval (2, 3) . Although this concept is valid for multiple daily dosing of ␤-lactam antibiotics, the pharmacokinetic and pharmacodynamic properties of aminoglycosides make them better suited for less frequent dosing. Aminoglycosides exhibit concentration-dependent killing (7, 12, 21) , such that bactericidal activity is augmented at higher antibiotic concentrations. As the concentration declines to a value below the MIC, the postantibiotic effect (PAE) of aminoglycosides allows for continued inhibition of bacterial growth (21, 22) . These two properties provide the therapeutic rationale for the administration of aminoglycosides in larger doses at longer intervals instead of smaller doses given more frequently.
In animal models and in human clinical trials, the effectiveness of OD aminoglycoside therapy has been shown to be equivalent to or greater than that achieved with traditional multiple daily dosings (1, 3, 14) . The high concentrations achieved in serum with OD dosing raise concerns about the potentiation of nephrotoxicity, but less frequent dosing decreases the duration of exposure of proximal tubular cells to aminoglycosides and thus decreases accumulation in renal cells (12) . Several investigations have demonstrated that the risk of nephrotoxicity associated with aminoglycosides is not increased and may actually be reduced with less frequent dosing (2, 12, 14) ; the same may be true for ototoxicity, although information is limited (2, 12) .
OD administration of aminoglycosides for meningitis has not been evaluated. The low concentrations of aminoglycosides achieved in the cerebrospinal fluid (CSF) with traditional multiple daily dosing limits the effectiveness of these antibacterial agents when given alone for the treatment of gramnegative meningitis. With OD dosing, the higher concentrations achieved in serum should result in higher concentrations in CSF. However, because the CSF in patients with meningitis is an area devoid of antibody and complement necessary for bacterial defense, the relevance and duration of PAE are unknown (15, 19) and prolonged dosing intervals may be inadequate. The purpose of our studies was to assess the bacteriologic efficacy of OD therapy in the treatment of experimental Escherichia coli meningitis. By using the well-characterized rabbit meningitis model, two regimens of the same daily dosage, given either once or in three divided doses, were compared in terms of CSF penetration and bacterial clearance.
(This study was presented in part at the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, Calif., 19 September 1995.)
MATERIALS AND METHODS
Test organism. E. coli 77-36, a K1:O18 strain originally isolated from a neonate with meningitis, was used in all experiments. Colonies grown overnight on blood agar were suspended in Mueller-Hinton broth, incubated at 37ЊC for 8 to 10 h, and washed twice in endotoxin-free phosphate-buffered saline. The inoculum was prepared by diluting the suspension in phosphate-buffered saline to a concentration of 10 4 to 10 5 CFU/ml, of which 250 l was used for intracisternal inoculation. Intrathecal passage of the organism in rabbits was performed regularly every 6 to 8 weeks, and the inoculum size was quantified with each experiment.
Susceptibility testing. The MIC and the minimal bactericidal concentration (MBC) of gentamicin were measured in Mueller-Hinton broth by a standard microdilution method (13) . The MIC was defined as the lowest concentration inhibiting visible growth after 16 to 20 h of incubation at 35ЊC in room air. The lowest drug concentration that killed Ն99.9% of the inoculum was defined as the MBC.
Meningitis model. The well-characterized rabbit meningitis model, modified from the original description by Dacey and Sande (6), was used. All studies were approved and monitored by the Institutional Animal Care and Research Advisory Committee (IACRAC) of the University of Texas Southwestern Medical Center. New Zealand White male rabbits (weight, 2 to 2.5 kg) were anesthetized by the intramuscular administration of ketamine (50 mg/kg of body weight) and acepromazine (4 mg/kg) before every procedure. Animals were immobilized in stereotactic frames, and a spinal needle was introduced into the cisterna magna to withdraw 250 l of CSF and to inject an equal volume of inoculum. Treatment was initiated 10 h after inoculation once CSF was withdrawn for quantitation of initial bacterial titers. According to a modification of the protocol reviewed by IACRAC, the infected animals used in the last five experiments received flunixin meglumine (1.1 mg/kg) every 12 h for pain control. Use of this agent was limited to those experiments in which gentamicin was administered intracisternally. Animals were euthanized with pentobarbital (120 mg/kg) at the end of each experiment and during the experiments if they appeared severely lethargic or were unable to maintain recumbency.
Antimicrobial agents. Gentamicin sulfate (SoloPak Laboratories, Elk Grove Village, Ill.) was administered intravenously over 3 to 5 min at a dosage of either 10.5 mg/kg every 24 h or 3.5 mg/kg every 8 h. The smaller dosage was chosen to achieve peak concentrations in serum similar to those observed in the sera of humans receiving conventional therapy, whereas the larger dosage was the sum of the doses in the three-dose regimen given as a single dose. For intracisternal (IC) administration, 0.1 or 0.2 mg of gentamicin per kg was diluted to a volume of 200 l with 0.9% NaCl and was injected as a single dose into the cisterna magna after removal of an equal volume of CSF. IC dosages were similar to those previously used in rabbits and were shown not to produce neurotoxicity (9, 23) .
Sample collection and processing. Twenty-four-hour experiments were conducted to compare the pharmacokinetics and bacteriologic efficacies of the two intravenous dosing regimens. In these experiments, blood was collected from the ear artery at 0.5, 1, 8, 8.5, 9, 16, 16.5, 17 , and 24 h of therapy, and cisternal CSF was sampled at 1, 8, 9, 16, 17, and 24 h of therapy. Seventy-two-hour experiments were conducted to compare the efficacies of the two dosing regimens. In these latter studies, blood and CSF were sampled at 24, 48, and 72 h of therapy. For experiments with IC therapy, CSF was sampled 8, 16, and 24 h after the administration of gentamicin.
Bacterial concentrations were quantified by plating undiluted and serial dilutions of CSF (100 l) onto sheep blood agar and incubating the plates at 37ЊC in room air. The detection limit by this method was 10 CFU/ml. Samples with Ͻ10 CFU/ml were assigned a value of 10 CFU/ml (1 log 10 ). The remaining CSF and blood samples were centrifuged at 5,000 ϫ g for 5 and 10 min, respectively, and the supernatants were stored at Ϫ70ЊC for determination of antibiotic concentrations.
Antibiotic assays. Gentamicin concentrations in serum and CSF were determined by a disk diffusion microbioassay with Bacillus subtilis ATCC 6633 (Difco Laboratories, Detroit, Mich.). The lower limit of detection was 0.1 g/ml for serum and CSF samples. Interassay and intra-assay coefficients of variation for CSF samples were 4.0 and 3.1%, respectively, and those for serum samples were 2.9 and 3.0%, respectively.
Statistical analysis. All results are expressed as means Ϯ standard deviations. Comparisons between groups for bacteriologic efficacy were performed by oneway analysis of variance by Newman-Keuls multiple comparisons test. The Student t test was used for paired data. A P value of Ͻ0.05 was considered significant.
RESULTS
In vitro susceptibility. The MIC and MBC of gentamicin for the E. coli strain used were 0.5 and 1.0 g/ml, respectively. Mean values are presented in Table 1 . The serum half-lives of gentamicin were 0.65 and 0.72 h for the SD and MD groups, respectively; these values are similar to those previously reported for rabbits (5) . The mean levels of penetration of gentamicin into CSF at 1 h, defined as the (mean concentration in CSF/mean concentration in serum) ϫ 100, were 25 and 21% for the SD and MD groups, respectively.
(ii) IC therapy. Seven animals received gentamicin at 0.1 mg/kg and 9 received the drug at 0.2 mg/kg as single IC doses. Mean Ϯ standard deviation CSF gentamicin concentrations were as follows: 4.0 Ϯ 1.0, 1.5 Ϯ 0.8, and 0.8 Ϯ 0.8 g/ml at 8, 16, and 24 h, respectively, for the smaller dosage and 13.1 Ϯ 12.2, 4.1 Ϯ 2.7, and 1.4 Ϯ 1.1 g/ml at 8, 16, and 24 h, respectively, for the larger dosage. In two animals receiving the higher dosage, the concentrations in CSF 1 h after dosing were 157 and 129 g/ml, respectively, and 2 h after dosing they were 54 and 35 g/ml, respectively. No evidence of neurotoxicity such as ataxia or seizure activity was observed with IC gentamicin administration.
Bacteriologic effect. Bacteriologic effect was defined as rate of bacterial clearance or the mean change in the numbers of CFU (log 10 per milliliter) over time.
(i) Twenty-four-hour experiments. The mean bacterial counts in CSF calculated at 8-h intervals in 15 animals in the SD group and 12 animals in the MD group are presented in Fig. 1 , and the rates of killing per hour for 8-h intervals are presented in Table 2 . Initial mean bacterial titers in CSF were similar for treated and untreated animals. Compared with 
FIG. 1. Mean Ϯ standard deviation bacterial concentrations in CSF of rabbits following IC inoculation of E. coli. Animals were treated for 24 h with intravenous gentamicin at a dosage of 10.5 mg/kg every 24 h (SD group; squares) or 3.5 mg/kg every 8 h (MD group; triangles) or were not treated (circles). ‫,ء‬ P Ͻ 0.05 for mean change in CFU (log 10 per milliliter) for animals in the SD group versus untreated animals from 0 to 8 and 0 to 16 h; only one of eight control animals survived to 24 h; ‫,ءء‬ P Ͻ 0.05 for mean reduction in CFU for animals treated OD versus animals treated thrice daily from 0 to 8 h. Of the 15 animals in the SD group and the 14 treated animals in the MD group, all survived to 8 h, 15 animals in the SD group and 10 animals in the MD group survived to 16 h, and 14 (93%) animals in the SD group and 8 (57%) animals in the MD group survived to the completion of the experiment. CSF samples from none of the animals surviving to the completion of the experiment were sterile on culture.
eight untreated animals, bacterial clearance defined by the mean reduction in bacterial counts (change in log 10 CFU/ml) was significantly greater for animals in the SD group at 8 h (P ϭ 0.03) and at 16 h of therapy (P ϭ 0.05); only one untreated animal survived to 24 h. From 0 to 8 h, the reduction in bacterial counts was significantly greater for the SD group than the MD group (Ϫ1.67 Ϯ 1.5 versus Ϫ0.24 Ϯ 1.8; P ϭ 0.03), as was the rate of bacterial clearance (Table 2 ), but the difference was no longer significant by 24 h of therapy. None of the CSF samples from animals in the treatment groups were sterile on culture at the end of the 24-h experiments.
(ii) Seventy-two-hour experiments. Mean bacterial counts in CSF calculated at 24-h intervals in 13 animals in the SD group and 20 animals in the MD group are presented in Fig. 2 and are compared with those in three untreated animals. Bacterial titers before the initiation of therapy were similar for the treated and untreated animals: 6.2 Ϯ 1.3 log 10 CFU/ml (SD group), 6.2 Ϯ 1.2 log 10 CFU/ml (MD group), and 7.0 Ϯ 0.5 log 10 CFU/ml (control group). Mean cumulative changes in bacterial counts for the SD group were Ϫ3.0 Ϯ 2.5 log 10 CFU/ml (0 to 24 h), Ϫ4.4 Ϯ 1.3 log 10 CFU/ml (0 to 48 h), and Ϫ4.7 Ϯ 1.5 log 10 CFU/ml (0 to 72 h); and for the MD group they were Ϫ3.0 Ϯ 2.1 log 10 CFU/ml (0 to 24 h), Ϫ4.4 Ϯ 0.9 log 10 CFU/ml (0 to 48 h), and Ϫ4.5 Ϯ 0.8 log 10 CFU/ml (0 to 72 h). No significant differences in reductions of bacterial counts were noted between treatment groups at 24, 48, or 72 h of therapy. The mean reductions in the numbers of CFU at 24 h for both treatment groups in the 72-h experiments were greater than those at 24 h for both groups in the 24-h experiments ( Fig. 1 and 2 ). These differences were not significant given the large standard deviations of the mean numbers of CFU observed in this model. Only 7 of 13 (54%) animals in the SD group and 6 of 20 (30%) animals in the MD group survived to the completion of the experiment. The majority died from their disease or were sacrificed because of lethargy and an inability to drink, as stipulated by IACRAC. Analysis of bacterial clearance in only those animals surviving to the end of the experiments also showed no significant difference between the two regimens at any of the time points. Nonsurvivors in both groups had higher initial bacterial titers compared with those in survivors, but the difference was not statistically significant. Cultures of CSF from all animals surviving to the completion of the experiment were sterile.
(iii) Intracisternal therapy. The bacterial clearance achieved with the two different dosages of IC gentamicin is indicated in Fig. 3 . The mean reduction in the numbers of CFU and the rate of bacterial clearance did not significantly differ between the two dosage groups but were significantly greater by analysis of variance for both IC regimens compared with those for both intravenous regimens (P Ͻ 0.05) from 0 to 8 h.
DISCUSSION
Optimal treatment of bacterial meningitis requires attainment of adequate bactericidal activity in the CSF. Previous studies in the rabbit model suggested that the CSF antibiotic concentration is an important determinant of bacterial eradication and that peak concentrations in CSF correlate with bactericidal activity (15, 19, 20) . With ␤-lactam antibiotics, rapid bacterial killing was observed when CSF antibiotic concentrations were 10-to 20-fold higher than the MBC for the pathogen (15, 19) . Adequate bacterial killing with aminoglycosides also required high concentrations in CSF, varying from 5-to 30-fold above the MBC, depending on the pathogen and aminoglycoside (16, 18) .
Penetration of aminoglycosides into CSF is relatively high, varying from 15 to 25% of concurrent levels in serum (16) . The narrow therapeutic index of these antimicrobial agents, however, prevents achievement of high concentrations of the antibiotic in CSF. This together with the poor in vivo activity of aminoglycosides in purulent CSF has limited the clinical use of these antibiotics alone for the treatment of gram-negative meningitis. With OD therapy, the therapeutic index of aminoglycosides is widened. The higher peak concentrations in se-FIG. 2. Mean Ϯ standard bacterial concentrations in CSF of rabbits following IC inoculation of E. coli. Animals were treated for 72 h with intravenous gentamicin at a dosage of 10.5 mg/kg every 24 h (SD group; squares) or 3.5 mg/kg every 8 h (MD group; triangles) or were not treated (circles). ‫,ء‬ P Ͻ 0.05 for mean reduction in CFU (log 10 per milliliter) for treated versus untreated animals from 0 to 24 h. There was no significant difference in reduction of bacterial titers between treatment groups. Of the 13 treated animals in the SD group and 20 treated animals in the MD group, 12 and 11 survived to 24 h, 9 and 6 survived to 48 h, and 7 (54%) and 6 (30%) survived to the completion of the experiment, respectively. rum can be expected to yield higher concentrations in CSF but may result in a longer period of subinhibitory concentrations compared with intermittent therapy. The purpose of our investigation was to determine the impact of OD therapy for the treatment of experimental E. coli meningitis.
Aminoglycosides exhibit concentration-dependent killing both in vitro and in vivo (3, 4, 7, 10) . In animal models, this observation translates to an improved therapeutic outcome at higher peak concentrations in serum (3, 10) . The majority of animal studies have shown at least equivalent or improved efficacy when the total daily dose was administered at extended dosing intervals (3, 12, 14) . Evaluation of the efficacy of OD dosing in the meningitis model is unique in that the drug concentration of relevance is found not in the serum but rather in the CSF, a second compartment with different pharmacokinetics. In this study, mean peak concentrations in serum at 0.5 and 1 h were threefold higher in the SD group than in the MD group, as would be predicted by the linear pharmacokinetics of aminoglycosides. These peak concentrations in serum were similar to those observed in humans after OD and conventional dosings (7, 10) . With similar penetration for the two regimens, the resultant absolute concentration in CSF at 1 h was also threefold higher for the SD regimen. That the rate of bacterial clearance in the first 8 h of therapy was significantly more rapid for the SD group with the higher peak concentration in CSF suggests concentration-dependent killing in this compartment. After 17 h of therapy, the CSF gentamicin concentration in the MD group accumulated to a value similar to the peak concentration observed in the CSF of the SD group, and in the ensuing 8 h after the administration of that third dose, the rate of bacterial clearance was comparable to that seen in the SD group after administration of the first dose (Table 2) .
To investigate further concentration-dependent bactericidal activity, IC gentamicin therapy was used to achieve very high CSF antibiotic concentrations. The mean concentrations measured in the CSF of two animals at 1 h and in all animals at 8 h after dosing were significantly higher than the peak concentrations attained with either intravenous regimen at the same time points. Bacterial clearance from 0 to 8 h was significantly greater for the IC regimens compared with those for intravenous regimens (Table 2) , and for 9 of 16 intracisternally treated animals, rates of bacterial killing were greater than 0.5 log 10 CFU/ml/h, whereas for only 3 of 29 animals treated intravenously were bacterial killing rates greater than 0.5 log 10 CFU/ml/h. There was a statistically significant correlation between the gentamicin concentration in CSF and the rate of bacterial killing (r ϭ 0.54; P ϭ 0.04). These findings provide further evidence for concentration-dependent killing by gentamicin in experimental meningitis. At 24 h of therapy, CSF samples from three of seven animals receiving the lower dosage and five of nine animals receiving the higher dosage were sterile on culture, whereas samples from none of the animals treated intravenously were sterile on culture.
PAE, defined as the continued suppression of bacterial growth after brief exposure to an antibiotic, was initially observed with ␤-lactam antibiotics and gram-positive organisms 50 years ago (22, 25) . Recent extension of this observation to aminoglycosides and gram-negative organisms has challenged the belief that adequate bactericidal activity requires the maintenance of concentrations in serum above the MBC for the majority of a dosing interval. In vitro, the duration of PAE of aminoglycosides ranges from 2 to 6 h for gram-negative organisms. It is prolonged in vivo (21, 22) and at higher antibiotic concentrations (12, 22, 25) , further supporting the use of larger drug doses administered less frequently. The relevance of this phenomenon in meningitis, however, is unknown. Although the present study was not designed to measure the PAE of gentamicin in E. coli meningitis, it is noteworthy that in the SD group, bacterial clearance continued for at least two-thirds of the dosing interval, during which time the concentrations in the CSF of many animals were at or below the MBC. This suggests that an in vivo PAE exists and that CSF gentamicin concentrations need not be maintained above the MBC for the majority of the dosing interval to ensure bacterial clearance.
With evidence for concentration-dependent activity and a possible PAE in this model, the SD regimen could be expected to demonstrate greater efficacy compared with that of the MD regimen. Although the SD regimen appeared to be more effective in the first 8 h of therapy, there was no difference in bacterial clearance by 24 h, and comparable efficacy was again demonstrated in the 72-h experiments. That the two intravenous dosing regimens did not differ in bacteriologic effect might be attributed to the unique characteristics of antimicrobial pharmacokinetics in CSF. Unlike the gentamicin concentrations in serum, the gentamicin concentration in CSF accumulated in the animals receiving multiple doses, perhaps as a result of the slow elimination of antibiotics in this compartment (19) . Although there is believed to be an active transport mechanism for aminoglycosides in the choroid plexus (11, 17) , this mechanism may be ineffective in the early phases of inflammation, as demonstrated for ␤-lactams in children with meningitis (8, 24) . The accumulation of antibiotic resulted in increased bacterial clearance in the MD group after the third dose, and the cumulative reduction in bacterial counts was comparable for the two regimens by 24 h. Whether gentamicin continued to accumulate during the second or third day is unclear; as inflammation resolves, active transport of antibiotics may be expected to resume baseline function.
Mortality and morbidity among animals was a consistent finding in our experiments. Loss of animals occurred most notably in the 72-h experiments, during which animals were minimally manipulated, undergoing only four cisternal punctures at 24-h intervals. The loss of animals was higher in the MD group (70%) compared with that in the SD group (46%), but it is impossible to correlate directly mortality with the treatment regimen. The high mortality rates observed are not unexpected for animals with gram-negative meningitis studied for 24 to 72 h. FIG. 3 . Mean Ϯ standard deviation bacterial concentrations in CSF of rabbits with experimental E. coli meningitis treated with IC gentamicin. Nine animals were treated with 0.1 mg/kg (squares) and seven were treated with 0.2 mg/kg (triangles) as single doses. There was no significant difference in mean reduction in CFU (log 10 per milliliter) between the two dosage groups. ‫,ء‬ P Ͻ 0.05 for mean reduction in CFU from 0 to 8 h for both IC treatment groups versus both intravenous treatment groups (Fig. 1) . All intracisternally treated animals survived to the end of the 24-h experiments. ‫,ءء‬ standard deviation for the datum point is Ϯ0.13.
In summary, SD gentamicin therapy appears to be as effective as MD therapy for experimental E. coli meningitis. The higher intravenous dosage in the SD regimen results in higher concentrations in CSF early in therapy, with greater reductions in bacterial titers, although no difference is noted 24 h after the initiation of therapy, and time to sterilization of CSF is similar for both regimens. Clinical application of these findings and extrapolation of the data to humans are uncertain. Although the rabbit model is useful for predicting the penetration and potential bacteriologic efficacy of antimicrobial agents for meningitis, the differences in formation and circulation of CSF as well as differences in pharmacokinetics between humans and rabbits limits the applicability of these observations. The role of OD aminoglycoside therapy for gram-negative meningitis in humans remains to be established.
